NCE-1 Intelligence & Market Opportunity

Filsuvez

Birch Triterpenes

Dermatologic

Topical Gel

Filsuvez is a topical gel used on open wounds in patients with dystrophic or junctional epidermolysis bullosa (EB). It’s the first treatment that supports skin healing in this condition by promoting wound closure.

Approval Date

18-Dec-23

NCE-1 Date

18-Dec-27

NCE Date

18-Dec-28

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Birch Triterpenes

Innovator

CHIESI FARMACEUTICI SPA

Dosage Form

Topical Gel

Strength

10%

Therapeutic Category

Dermatologic

Usage

To treat wounds associated with dystrophic and junctional epidermolysis bullosa

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets